Compare IDEXX Laboratories, Inc. (IDXX) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NICE Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $572.03 (market cap $46.22B), while NICE Ltd trades at $97.55 (market cap $6.02B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.7× NICE Ltd's market cap. Which is the better fit depends on your goals.
| IDXX | NICE | |
|---|---|---|
Market Cap | $46.22B | $6.02B |
Sector | Health | Technology |
52-Week High | $766.68 | $153.44 |
52-Week Low | $526.44 | $83.15 |
Enterprise Value | $47.12B | $5.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
NICE stock trades at $98.71, down 3.76% today, but maintains a bullish technical outlook with support near $99. The company reported Q2 2026 earnings beats, with revenue growth of 7.6% year-over-year to $782.3 million (Business Wire, 2026-08-05). Valuation metrics appear reasonable with a P/E of 14.8 and P/S of 2.03. Recent news highlights partnerships with Currys and RingCentral to enhance AI-driven customer engagement.
The investment outlook is positive, supported by strong analyst consensus with a $115 price target (52% buy ratings). Key opportunities include cloud and AI growth, while risks involve execution challenges and potential margin pressure from increased investments. The stock offers ~16.5% upside to the consensus target, but investors should monitor Q3 2026 earnings due to expected EPS of 2.76.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
